Mylan buys API plant in India

Active pharmaceutical ingredients (API), intermediates and formulations manufacturer SMS Pharmaceuticals (Hyderabad, India) informed the Bombay Stock Exchange (Mumbai) that its board of directors has decided to sell its plant at Visakhapatnam, India, to Mylan Laboratories (Hyderabad), a subsidiary of Mylan (Canonsburg, PA), for 1.73 billion Indian rupees ($33 million). The plant manufactures APIs and formulations for oncology drugs.